Product: Gelato Artigianale al gusto di Raspberry Gelato
Companies: Angelo's Italian Market Inc. (London, ON)
Issue: Food ? Microbial contamination ? Norovirus
Category: Dairy
What to do: Do not consume, use, sell, serve, or distribute recalled products
Audience: General public
Recall class: Class 2
Affected products
Brand
Product
Size
UPC
Code
None
Gelato Artigianale
al gusto di Raspberry Gelato
1 L
0 000000 067430
None ? Sold at Angelo's Italian Market Inc., 755 Wonderland Road North, London, ON up to and including June 14, 2022
Issue
The affected product is being recalled from the marketplace due to possible norovirus contamination of the raspberries used in this product.
The recalled product has been sold at Angelo's Italian Market Inc. (London, ON).
What you should do
If you think you became sick from consuming a recalled product, contact your healthcare provider
Check to see if you have recalled products
Do not consume, serve, use, sell, or distribute recalled products
Recalled products should be thrown out or returned to the location where they were purchased
People with norovirus illness usually develop symptoms of gastroenteritis within 24 to 48 hours, but symptoms can start as early as 12 hours after exposure. The illness often begins suddenly. Even after having the illness, you can still become re-infected by norovirus. The main symptoms of norovirus illness are diarrhea, vomiting (children usually experience more vomiting than adults), nausea and stomach cramps. Other symptoms may include low-grade fever, headache, chills, muscle aches and fatigue (a general sense of tiredness). Most people feel better within one or two days, with symptoms resolving on their own, and experience no long-term health effects. As with any illness causing diarrhea or vomiting, people who are ill should drink plenty of liquids to replace lost body fluids and prevent dehydration. In severe cases, patients may need to be hospitalized and given fluids intravenously.
The Foundation Fighting Blindness, the driving force in the global development of treatments and cures for blinding diseases, will host its VISIONS 2024 conference at the Chicago Marriott Downtown Magnificent Mile on June 21?22, 2024. This biennial...
Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new groundbreaking algorithm, SignalHF1, used...
The American Trucking Associations is calling attention to the negative consequences for highway safety and safety-sensitive industries that could result from the U.S. Drug Enforcement Administration's proposal to reschedule marijuana from a Schedule...
- AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD)- Data to be presented from...
We are advised by OsteoStrong that journalists and other readers should disregard the news release, OsteoStrong Celebrates Success and Innovation at 11th Annual Global Franchise Owner Convention, issued May 9, 2024 over PR Newswire.
SOURCE...
Precision BioSciences, Inc. , an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today...